Cargando…

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting

INTRODUCTION: There is a lack of data comparing the protease inhibitors (PIs) atazanavir (ATV) and darunavir (DRV) in a real-world setting. This study compared persistence (time to switch/discontinuation) to therapy between ATV-treated and DRV-treated patients with human immunodeficiency virus (HIV)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farr, Amanda M, Johnston, Stephen S, Ritchings, Corey, Brouillette, Matthew, Rosenblatt, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P006
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224837/ https://www.ncbi.nlm.nih.gov/pubmed/25394047 http://dx.doi.org/10.7448/IAS.17.4.19538

Ejemplares similares

Virtual Outpatient Heart Failure Care - Lessons From the Covid-19 Era
por: Ugolini, Sharon, et al.
Publicado: (2020)

Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy
por: Antinori, Andrea, et al.
Publicado: (2014)

CORRELAÇÃO DA GRAVIDADE CLÍNICA DE PESSOAS VIVENDO COM HIV COINFECTADAS COM COVID‐19 E FATORES DE RISCO IMUNO‐VIROLÓGICOS
por: Lima, Luan Victor Almeida, et al.
Publicado: (2021)

Effective Intervention and Vaccination Strategies Against Nosocomial Infection Based on Network Analysis
por: Ueno, T., et al.
Publicado: (2008)

Incidence et pronostic de la COVID-19 chez les malades atteints de maladie bulleuse auto-immune
por: Aouar, K., et al.
Publicado: (2020)

L’apparition d’une polyarthrite rhumatoïde post-vaccinale: un effet indésirable potentiel des vaccins à ARNm?
por: Alaya, R., et al.
Publicado: (2021)

CAUSAS DE ÓBITOS EM PACIENTES COM COVID-19 EM UM HOSPITAL DE REFERÊNCIA DE SALVADOR (BA)
por: Pereira, Alana Coleta L., et al.
Publicado: (2022)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Cardiovascular outcomes among HIV-infected veterans receiving atazanavir
por: LaFleur, Joanne, et al.
Publicado: (2017)

Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review
por: Chow, Dominic, et al.
Publicado: (2016)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy
por: Estrada, Vicente, et al.
Publicado: (2014)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment
por: Sweet, Donna, et al.
Publicado: (2014)

Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
por: Giacomelli, Andrea, et al.
Publicado: (2014)

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2014)

Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI-free regimens
por: Nkhoma, Ella, et al.
Publicado: (2014)

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression
por: Llibre, Josep M, et al.
Publicado: (2014)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial
por: Fabbiani, Massimiliano, et al.
Publicado: (2014)

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study
por: Portilla, Joaquín, et al.
Publicado: (2014)

Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
por: Antinori, Andrea, et al.
Publicado: (2014)

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach
por: Dickinson, Laura, et al.
Publicado: (2014)

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre
por: Borghetti, Alberto, et al.
Publicado: (2014)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up
por: Lanzafame, Massimiliano, et al.
Publicado: (2014)

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

Erratum to: Risk of cardiovascular events among patients with HIV treated with atazanavircontaining regimens: a retrospective cohort study
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

Severe birth defects in children perinatal exposed to HIV from a “real-world” setting: Infectious Diseases National Institute, Bucharest, Romania
por: Maria Tudor, Ana
Publicado: (2014)

Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults
por: Tashima, Karen, et al.
Publicado: (2014)

1572 Impact of Hyperbilirubinemia on Persistence and Adherence of Atazanavir among HIV Patients
por: Rosenblatt, Lisa, et al.
Publicado: (2014)

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014)

Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
por: Peng, Siyang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_h0dirramdgj4gt9eri8qv3sosg